Creso Pharma Limited
COPHF · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $8 | $50 | $46 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $8 | $50 | $46 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 117.8% | 39.7% | 154% | – |
| Gross Profit | $0 | $0 | -$0 | -$0 |
| % Margin | 12.3% | 3.3% | -6.4% | -158.6% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -133% | -202.8% | -451.2% | -673.5% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -277.2% | -377.3% | -510.8% | -1,535.2% |
| EPS Diluted | 0 | -0.022 | -0.029 | -0.1 |
| % Growth | 100% | 22% | 71.3% | – |
| Operating Cash Flow | $0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |